A single‐center, open‐label, randomized cross‐over study to evaluate the pharmacokinetics and bioavailability of once‐daily prolonged‐release formulations of tacrolimus in de novo liver transplant recipients
Abstract Background The narrow therapeutic window of tacrolimus (Tac) requires intense drug monitoring to achieve adequate efficacy while minimizing dose‐related toxicities. Once‐daily formulations of Tac (LCP‐Tac and PR‐Tac) have been recently designed for higher bioavailability and a more consiste...
Guardado en:
Autores principales: | Uta Herden, Martina Sterneck, Bettina M. Buchholz, Eike G. Achilles, Armin Ott, Lutz Fischer |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Wiley
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/78bb400793f54590859ccfbee5c26e98 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Genetic Polymorphisms Affecting Tacrolimus Metabolism and the Relationship to Post-Transplant Outcomes in Kidney Transplant Recipients
por: Cheng F, et al.
Publicado: (2021) -
Novel in situ self-assembly nanoparticles for formulating a poorly water-soluble drug in oral solid granules, improving stability, palatability, and bioavailability
por: Guo S, et al.
Publicado: (2016) -
Human kidney organoids model the tacrolimus nephrotoxicity and elucidate the role of autophagy
por: Jin Won Kim, et al.
Publicado: (2021) -
Pharmacogenetics Based Dose Prediction Model for Initial Tacrolimus Dosing in Renal Transplant Recipients
por: Lekshmy Srinivas, et al.
Publicado: (2021) -
Nicotine exacerbates tacrolimus-induced renal injury by programmed cell death
por: Yu Ji Jiang, et al.
Publicado: (2021)